Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine.

Pauli, Chantal; Hopkins, Benjamin D; Prandi, Davide; Shaw, Reid; Fedrizzi, Tarcisio; Sboner, Andrea; Sailer, Verena; Augello, Michael; Puca, Loredana; Rosati, Rachele; McNary, Terra J; Churakova, Yelena; Cheung, Cynthia; Triscott, Joanna Catherine Caprio; Pisapia, David; Rao, Rema; Mosquera, Juan Miguel; Robinson, Brian; Faltas, Bishoy M; Emerling, Brooke E; ... (2017). Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine. Cancer discovery, 7(5), pp. 462-477. American Association for Cancer Research 10.1158/2159-8290.CD-16-1154

[img] Text
462.full.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (30MB) | Request a copy

Precision medicine is an approach that takes into account the influence of individuals' genes, environment, and lifestyle exposures to tailor interventions. Here, we describe the development of a robust precision cancer care platform that integrates whole-exome sequencing with a living biobank that enables high-throughput drug screens on patient-derived tumor organoids. To date, 56 tumor-derived organoid cultures and 19 patient-derived xenograft (PDX) models have been established from the 769 patients enrolled in an Institutional Review Board-approved clinical trial. Because genomics alone was insufficient to identify therapeutic options for the majority of patients with advanced disease, we used high-throughput drug screening to discover effective treatment strategies. Analysis of tumor-derived cells from four cases, two uterine malignancies and two colon cancers, identified effective drugs and drug combinations that were subsequently validated using 3-D cultures and PDX models. This platform thereby promotes the discovery of novel therapeutic approaches that can be assessed in clinical trials and provides personalized therapeutic options for individual patients where standard clinical options have been exhausted.Significance: Integration of genomic data with drug screening from personalized in vitro and in vivo cancer models guides precision cancer care and fuels next-generation research. Cancer Discov; 7(5); 462-77. ©2017 AACR.See related commentary by Picco and Garnett, p. 456This article is highlighted in the In This Issue feature, p. 443.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Präzisionsonkologie
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Präzisionsonkologie

UniBE Contributor:

Triscott, Joanna Catherine Caprio and Rubin, Mark Andrew

Subjects:

500 Science > 570 Life sciences; biology

ISSN:

2159-8290

Publisher:

American Association for Cancer Research

Language:

English

Submitter:

Basak Ginsbourger

Date Deposited:

12 Feb 2018 08:01

Last Modified:

22 Oct 2019 18:28

Publisher DOI:

10.1158/2159-8290.CD-16-1154

PubMed ID:

28331002

BORIS DOI:

10.7892/boris.110988

URI:

https://boris.unibe.ch/id/eprint/110988

Actions (login required)

Edit item Edit item
Provide Feedback